NCT01945268View on ClinicalTrials.gov

Influenza Vaccine To Prevent Adverse Vascular Events:Pilot

PHASE4CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Heart Failure
Interventions
DRUG

inactivated trivalent influenza vaccine

0.5 ml dose injected intramuscularly

OTHER

Sterile saline

0.5 ml dose injected intramuscularly

Trial Locations (3)

Unknown

Maputo Central Hospital, Maputo

University of Philippines, Manila

Mulago Hospital, Kampala

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

lead

McMaster University

OTHER

NCT01945268 - Influenza Vaccine To Prevent Adverse Vascular Events:Pilot | Biotech Hunter | Biotech Hunter